Estrogen Receptor Alpha Expression in Ovarian Cancer Predicts Longer Overall Survival
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Estrogen as a potential factor of ovarian carcinogenesis, acts via two nuclear receptors, estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ), but the cellular signal pathways involved are not completely clear so far. In this study we have described the expression of ERα, detected by immunocytochemistry in 11 ovarian carcinoma cell lines and by immunohistochemistry in 43 Federation Internationale des Gyneacologistes et Obstetristes stage III ovarian carcinoma specimens prepared before and after treatment with cisplatin-based schemes. For cisplatin resistance is a major obstacle in the treatment of ovarian carcinoma, analysis of cisplatin sensitivity in 11 ovarian carcinoma cell line was also performed. The strong nuclear ERα expression was only shown in the single A2780P cell line. Expression of ERα in tissue specimens did not reveal any correlations between histopathological parameters (histologic type and grading). We demonstrated a significant association with ERα expression in specimens from primary laparotomies (PL) and cause-specific survival. In the cases terminated by death of the patient, overall immunoreactivity score of ERα expression at PL was significantly lower than in surviving patients. In addition, Kaplan-Meier analysis revealed significantly shorter overall survival time and progression-free time in cases with lower immunoreactivity score of ERα expression at PL. Our findings support the hypothesis that aberrant hormone activity, by way of altered receptor expression, might be an important factor in the malignant transformation of ovarian cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recent advances in the treatment of epithelial ovarian cancer
Harries, M., & Kaye, S. B. (2001) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.10.9.1715 · Cited by 54 · cited 1×
“From the previous data, the role of tamoxifen in ovarian cancer has not been properly evaluated, although some authors postulated that combined therapy with cisplatin and tamoxifen might reduced cisplatin resistance [10, 11]”
Cited by
EDC-2: the endocrine society's second scientific statement on endocrine-disrupting chemicals
Gore, A. C., Chappell, V. A., Fenton, S. E., Flaws, J. A., Nadal, A., Prins, G. S., Toppari, J., & Zoeller, R. T. (2015) · Endocrine Reviews · doi:10.1210/er.2015-1010 · Cited by 2,407
Gibson, D. A., & Saunders, P. T. K. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.09.026 · Cited by 107
Ciucci, A., Zannoni, G. F., Buttarelli, M., Lisi, L., Travaglia, D., Martinelli, E., Scambia, G., & Gallo, D. (2016) · Oncotarget · doi:10.18632/oncotarget.6943 · Cited by 46
Metadata
- Authors
- Halon, A., Materna, V., Drag-Zalesinska, M., Nowak-Markwitz, E., Gansukh, T., Donizy, P., Spaczynski, M., Zabel, M., Dietel, M., Lage, H., & Surowiak, P.
- Venue
- Pathology & Oncology Research
- Published
- 2011-01-06
- Volume
- 17
- Issue
- 3
- Pages
- 511-518
- ISSN
- 1219-4956 (ISSN-L)
- 1532-2807
- OpenAlex
- W2074835867
- Cited by
- 59
- References
- 1
- FWCI
- 8.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Estrogen Receptor Alpha Expression in Ovarian Cancer Predicts Longer Overall Survival. https://app.cochat.ai/papers/10.1007/s12253-010-9340-0
- The paper
- Halon, A., Materna, V., Drag-Zalesinska, M., Nowak-Markwitz, E., Gansukh, T., Donizy, P., Spaczynski, M., Zabel, M., Dietel, M., Lage, H., & Surowiak, P. (2011). Estrogen Receptor Alpha Expression in Ovarian Cancer Predicts Longer Overall Survival. Pathology & Oncology Research. https://doi.org/10.1007/s12253-010-9340-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.